CoChat

Tonic endocannabinoid-mediated modulation of GABA release is independent of the CB1 content of axon terminals

Open access
Lenkey, Nora, Kirizs, Tekla, Holderith, Noemi, Máté, Zoltán, Szabó, Gábor, Vizi, E. Sylvester, Hájos, Norbert, Nusser, Zoltan · 2015 · Nature Communications

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.

Abstract

The release of GABA from cholecystokinin-containing interneurons is modulated by type-1 cannabinoid receptors (CB 1). Here we tested the hypothesis that the strength of CB 1-mediated modulation of GABA release is related to the CB 1 content of axon terminals. Basket cell boutons have on average 78% higher CB 1 content than those of dendritic-layer-innervating (DLI) cells, a consequence of larger bouton surface and higher CB 1 density. The CB 1 antagonist AM251 caused a 54% increase in action potential-evoked [Ca 2+] in boutons of basket cells, but not in DLI cells. However, the effect of AM251 did not correlate with CB 1 immunoreactivity of individual boutons. Moreover, a CB 1 agonist decreased [Ca 2+] in a cell type- and CB 1-content-independent manner. Replica immunogold labelling demonstrated the colocalization of CB 1 with the Cav2.2 Ca 2+ channel subunit. Our data suggest that only a subpopulation of CB 1 s, within nanometre distances from their target Cav2.2 channels, are responsible for endocannabinoid-mediated modulation of GABA release.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/ncomms7557

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Variability in CB 1 content of axon terminals in the CA3 region of the hippocampus. (a) CB1 immunofluorescent labelling is different in distinct layers of the mouse hippocampus, and it is stronger in the distal CA3 (between white arrows) than in the proximal CA3 (between red arrows). In the distal CA3, the stratum pyramidale is more intensely labelled than the strata oriens, lucidum and radiatum. (b) The boxed area in a is shown at a higher magnification. (c) There is high variability in the CB1 content among individual boutons. Axon terminals with weak (red arrows), strong (white arrows) and intermediate (orange arrows) CB1 immunoreactivity (CB1-IR) can be found in the stratum pyramidale of the distal CA3. (d,e) CB1 immunofluorescent reactions on sections obtained from a transcardially perfused mouse (d) and a rat (e). Individual boutons in stratum pyramidale have strong CB1-IR, whereas axon terminals in strata oriens, lucidum and radiatum contain comparable levels of CB1-IR. Note that within each region, there is bouton-to-bouton variability in the CB1 content. (f–h) Relative CB1-IR of individual boutons in different layers of the distal CA3 area of the hippocampus normalized to the mean CB1 intensity of boutons in stratum radiatum. The CB1 content similarly changes between layers in slices derived from in vitro imaging experiments (f), perfused mouse (g) and rat (h) sections. Randomized block design ANOVA was performed on the data sets before normalization, and significant difference between groups was found for the in vitro mouse (P<0.001, n=6), perfused mice (P<0.001, n=5) and perfused rat (P<0.001, n=4) data. Tukey post hoc test revealed a significant difference between stratum pyramidale and stratum oriens (P<0.001, P<0.001 and P=0.001), pyramidale and lucidum (P<0.001, P<0.001 and P=0.005) and pyramidale and radiatum (P<0.001, P<0.001 and P<0.001) for the in vitro slices, perfused mice and perfused rat sections, respectively. str. ori., stratum oriens; str. pyr., stratum pyramidale; str. luc, stratum lucidum; str. rad., stratum radiatum. Error bars in f–h represent s.d. Scale bars, 100 μm (a), 50 μm (b), 5 μm (c–e). *denotes P<0.05.
Figure 1 Variability in CB 1 content of axon terminals in the CA3 region of the hippocampus. (a) CB1 immunofluorescent labelling is different in distinct layers of the mouse hippocampus, and it is stronger in the distal CA3 (between white arrows) than in the proximal CA3 (between red arrows). In the distal CA3, the stratum pyramidale is more intensely labelled than the strata oriens, lucidum and radiatum. (b) The boxed area in a is shown at a higher magnification. (c) There is high variability in the CB1 content among individual boutons. Axon terminals with weak (red arrows), strong (white arrows) and intermediate (orange arrows) CB1 immunoreactivity (CB1-IR) can be found in the stratum pyramidale of the distal CA3. (d,e) CB1 immunofluorescent reactions on sections obtained from a transcardially perfused mouse (d) and a rat (e). Individual boutons in stratum pyramidale have strong CB1-IR, whereas axon terminals in strata oriens, lucidum and radiatum contain comparable levels of CB1-IR. Note that within each region, there is bouton-to-bouton variability in the CB1 content. (f–h) Relative CB1-IR of individual boutons in different layers of the distal CA3 area of the hippocampus normalized to the mean CB1 intensity of boutons in stratum radiatum. The CB1 content similarly changes between layers in slices derived from in vitro imaging experiments (f), perfused mouse (g) and rat (h) sections. Randomized block design ANOVA was performed on the data sets before normalization, and significant difference between groups was found for the in vitro mouse (P<0.001, n=6), perfused mice (P<0.001, n=5) and perfused rat (P<0.001, n=4) data. Tukey post hoc test revealed a significant difference between stratum pyramidale and stratum oriens (P<0.001, P<0.001 and P=0.001), pyramidale and lucidum (P<0.001, P<0.001 and P=0.005) and pyramidale and radiatum (P<0.001, P<0.001 and P<0.001) for the in vitro slices, perfused mice and perfused rat sections, respectively. str. ori., stratum oriens; str. pyr., stratum pyramidale; str. luc, stratum lucidum; str. rad., stratum radiatum. Error bars in f–h represent s.d. Scale bars, 100 μm (a), 50 μm (b), 5 μm (c–e). *denotes P<0.05.CC BY · PubMed Central
Figure 2 High-resolution immunogold localization of CB 1 in the distal CA3 area of the mouse hippocampus. (a–d) Variability in the CB1 content of boutons in distinct layers of the distal CA3 area. The CB1 labelling on the P-face of axon terminals (t) in stratum pyramidale (b) is more intense than in strata oriens (a), lucidum (c) and radiatum (d). (e) Randomized block design ANOVA followed by Tukey post hoc test (n=6) showed significant difference between strata pyramidale and lucidum (P=0.019), between strata pyramidale and radiatum (P<0.001) and between strata oriens and radiatum (P=0.014). The labelling in all four layers was significantly higher than the background (ANOVA: P<0.001; Tukey’s post hoc test: P<0.001; n=6 mice; 1.0±0.3 gold per μm2). Red diamonds indicate the mean±s.d. (f) Double-labelling experiments for CB1 (15 nm gold) and vesicular GABA transporter (VGAT, 10 nm gold) reveal that the CB1-immunolabelled profiles are GABAergic axon terminals (t2), but not all VGAT-labelled terminals contain CB1 (t1). (g) Background-subtracted density values for CB1 and VGAT of VGAT-immunopositive axon terminals are shown from two animals. Symbols represent individual boutons. (h–k) The CB1 immunolabelling is abolished in CB1−/− mice. A perisomatic axon terminal is co-labelled with two CB1 antibodies in a CB1+/+ mouse (t2 in h), while another is unlabelled (presumed parvalbumin-positive axon terminals, t1 in h). In CB1−/− mice only non-labelled profiles could be observed in the stratum pyramidale (t1 in i). A VGAT (10 nm gold) immunolabelled axon terminal is strongly CB1 immunopositive (15 nm gold, t2 in j) in a CB1+/+ mouse, but all VGAT-positive boutons are immunonegative in the CB1−/− tissue (t1 in k). str. ori., stratum oriens; str. pyr., stratum pyramidale; str. luc, stratum lucidum; str. rad., stratum radiatum; Rb, rabbit; Gp, guinea pig. All scale bars, 200 nm. *denotes P<0.05.
Figure 2 High-resolution immunogold localization of CB 1 in the distal CA3 area of the mouse hippocampus. (a–d) Variability in the CB1 content of boutons in distinct layers of the distal CA3 area. The CB1 labelling on the P-face of axon terminals (t) in stratum pyramidale (b) is more intense than in strata oriens (a), lucidum (c) and radiatum (d). (e) Randomized block design ANOVA followed by Tukey post hoc test (n=6) showed significant difference between strata pyramidale and lucidum (P=0.019), between strata pyramidale and radiatum (P<0.001) and between strata oriens and radiatum (P=0.014). The labelling in all four layers was significantly higher than the background (ANOVA: P<0.001; Tukey’s post hoc test: P<0.001; n=6 mice; 1.0±0.3 gold per μm2). Red diamonds indicate the mean±s.d. (f) Double-labelling experiments for CB1 (15 nm gold) and vesicular GABA transporter (VGAT, 10 nm gold) reveal that the CB1-immunolabelled profiles are GABAergic axon terminals (t2), but not all VGAT-labelled terminals contain CB1 (t1). (g) Background-subtracted density values for CB1 and VGAT of VGAT-immunopositive axon terminals are shown from two animals. Symbols represent individual boutons. (h–k) The CB1 immunolabelling is abolished in CB1−/− mice. A perisomatic axon terminal is co-labelled with two CB1 antibodies in a CB1+/+ mouse (t2 in h), while another is unlabelled (presumed parvalbumin-positive axon terminals, t1 in h). In CB1−/− mice only non-labelled profiles could be observed in the stratum pyramidale (t1 in i). A VGAT (10 nm gold) immunolabelled axon terminal is strongly CB1 immunopositive (15 nm gold, t2 in j) in a CB1+/+ mouse, but all VGAT-positive boutons are immunonegative in the CB1−/− tissue (t1 in k). str. ori., stratum oriens; str. pyr., stratum pyramidale; str. luc, stratum lucidum; str. rad., stratum radiatum; Rb, rabbit; Gp, guinea pig. All scale bars, 200 nm. *denotes P<0.05.CC BY · PubMed Central
Figure 3 SDS-FRL localization of RIM1/2 and Cav2.2 subunit on CB 1 -immunopositive axon terminals in the distal CA3 area of the mouse hippocampus. (a–b) Immunogold particles labelling CB1 (10 nm gold, t2) are present in the active zones (AZ; blue, labelled by Rim1/2 with 6 nm gold) of axon terminals. (c) P-face sections of CB1-immunopositive (t2 in c) and negative (t1 in c) axon terminals are attached to an E-face somatic plasma membrane. Both axon terminals contain a Rim1/2 positive AZ (blue). (d) Background-subtracted density values for CB1 and Rim1/2 measured in P-face axon terminal sections attached to the E-face membrane of pyramidal cell somata. A total of 69.2% of axon terminal fragments were double negative, while 9.2% were only Rim1/2, 7.2% were only CB1-positive and the remaining 14.4% contained both Rim1/2 and CB1 labelling. (e) A P-face axon terminal fragment attached to an E-face somatic membrane is co-labelled for CB1 and Cav2.2 subunit (t2), while another is unlabelled (t1). (f) Background-subtracted densities for CB1 and Cav2.2 subunit within P-face axon terminal sections. The CB1-positive profiles were either Cav2.2 positive or negative, but the majority (84.2%) of the Cav2.2 subunit-immunopositive profiles were CB1 positive. (g) Double-labelling experiments reveal that the P-face axon terminal fragments attached to E-face somatic membranes are labelled for either Cav2.2 (t2) or Cav2.1 (t1) subunit. The AZ of an excitatory axon terminal (t) contains large number of gold particles for both Cav2.2 and Cav2.1 subunits (orange, inset). (h) Background-subtracted density values for Cav2.2 and Cav2.1 of P-face bouton fragments. (i–k) The Cav2.2 subunit immunolabelling is abolished in Cav2.2−/− mice. Perisomatic axon terminals are labelled for Cav2.2 in CCK-BAC/DsRedT3 (t in i) and Cav2.2+/+ mice (t in j). In Cav2.2−/− mice only non-labelled profiles were observed in stratum pyramidale. Enlarged views of the boxed areas in a–c, e and g are shown on the right. str. ori., stratum oriens; str. luc, stratum lucidum; str. pyr., stratum pyramidale; Rb, rabbit; Gp, guinea pig. Scale bars, 500 nm (a–c,e,g); 100 nm, enlarged views of a–c and e; 200 nm, i–k and enlarged views and inset in g.
Figure 3 SDS-FRL localization of RIM1/2 and Cav2.2 subunit on CB 1 -immunopositive axon terminals in the distal CA3 area of the mouse hippocampus. (a–b) Immunogold particles labelling CB1 (10 nm gold, t2) are present in the active zones (AZ; blue, labelled by Rim1/2 with 6 nm gold) of axon terminals. (c) P-face sections of CB1-immunopositive (t2 in c) and negative (t1 in c) axon terminals are attached to an E-face somatic plasma membrane. Both axon terminals contain a Rim1/2 positive AZ (blue). (d) Background-subtracted density values for CB1 and Rim1/2 measured in P-face axon terminal sections attached to the E-face membrane of pyramidal cell somata. A total of 69.2% of axon terminal fragments were double negative, while 9.2% were only Rim1/2, 7.2% were only CB1-positive and the remaining 14.4% contained both Rim1/2 and CB1 labelling. (e) A P-face axon terminal fragment attached to an E-face somatic membrane is co-labelled for CB1 and Cav2.2 subunit (t2), while another is unlabelled (t1). (f) Background-subtracted densities for CB1 and Cav2.2 subunit within P-face axon terminal sections. The CB1-positive profiles were either Cav2.2 positive or negative, but the majority (84.2%) of the Cav2.2 subunit-immunopositive profiles were CB1 positive. (g) Double-labelling experiments reveal that the P-face axon terminal fragments attached to E-face somatic membranes are labelled for either Cav2.2 (t2) or Cav2.1 (t1) subunit. The AZ of an excitatory axon terminal (t) contains large number of gold particles for both Cav2.2 and Cav2.1 subunits (orange, inset). (h) Background-subtracted density values for Cav2.2 and Cav2.1 of P-face bouton fragments. (i–k) The Cav2.2 subunit immunolabelling is abolished in Cav2.2−/− mice. Perisomatic axon terminals are labelled for Cav2.2 in CCK-BAC/DsRedT3 (t in i) and Cav2.2+/+ mice (t in j). In Cav2.2−/− mice only non-labelled profiles were observed in stratum pyramidale. Enlarged views of the boxed areas in a–c, e and g are shown on the right. str. ori., stratum oriens; str. luc, stratum lucidum; str. pyr., stratum pyramidale; Rb, rabbit; Gp, guinea pig. Scale bars, 500 nm (a–c,e,g); 100 nm, enlarged views of a–c and e; 200 nm, i–k and enlarged views and inset in g.CC BY · PubMed Central
Figure 4 The CB 1 content of axon terminals in the distal CA3 is cell type-dependent, but independent of hippocampal layers. (a–d) Variability in the CB1 content of axon terminals of different cells. Post hoc immunohistochemical visualization of CB1 (green) in boutons (red) of in vitro [Ca2+] imaged and biocytin-filled GABAergic interneurons. Weakly (a,c) and strongly (b,d) CB1-immunopositive basket (a,b) and dendritic-layer-innervating (DLI, c,d) cells are shown. Lower panels display only the CB1 immunoreactivity (CB1-IR) for better visualization of the differences in the CB1 content. Arrows in upper and lower panels indicate the same boutons. (e) Basket cell axon terminals are stronger for CB1 than those of DLI cells in the distal CA3. The CB1-IR of biocytin-loaded boutons was normalized to the mean CB1 intensity of randomly selected non-biocytin-filled boutons in stratum pyramidale within the same section. (f–i) The strength of CB1-IR of boutons of a given cell is similar in different hippocampal layers. Both basket and DLI cells had axons in strata pyramidale (f,h) and radiatum (g,i). Lower panels show only the CB1-IR for better visualization of the differences in the CB1 content. (j) CB1-IR of axon terminals of individual cells is not significantly different in stratum pyramidale versus dendritic layers in basket and DLI cells. Error bars in e and j represent s.d. str. pyr., stratum pyramidale. Other str.: strata oriens, lucidum and radiatum. All scale bars, 2 μm. *denotes P<0.001.
Figure 4 The CB 1 content of axon terminals in the distal CA3 is cell type-dependent, but independent of hippocampal layers. (a–d) Variability in the CB1 content of axon terminals of different cells. Post hoc immunohistochemical visualization of CB1 (green) in boutons (red) of in vitro [Ca2+] imaged and biocytin-filled GABAergic interneurons. Weakly (a,c) and strongly (b,d) CB1-immunopositive basket (a,b) and dendritic-layer-innervating (DLI, c,d) cells are shown. Lower panels display only the CB1 immunoreactivity (CB1-IR) for better visualization of the differences in the CB1 content. Arrows in upper and lower panels indicate the same boutons. (e) Basket cell axon terminals are stronger for CB1 than those of DLI cells in the distal CA3. The CB1-IR of biocytin-loaded boutons was normalized to the mean CB1 intensity of randomly selected non-biocytin-filled boutons in stratum pyramidale within the same section. (f–i) The strength of CB1-IR of boutons of a given cell is similar in different hippocampal layers. Both basket and DLI cells had axons in strata pyramidale (f,h) and radiatum (g,i). Lower panels show only the CB1-IR for better visualization of the differences in the CB1 content. (j) CB1-IR of axon terminals of individual cells is not significantly different in stratum pyramidale versus dendritic layers in basket and DLI cells. Error bars in e and j represent s.d. str. pyr., stratum pyramidale. Other str.: strata oriens, lucidum and radiatum. All scale bars, 2 μm. *denotes P<0.001.CC BY · PubMed Central
Figure 5 Action potential-evoked [Ca 2+ ] transients are smaller in axon terminals of basket compared with DLI cells. (a) Two-photon Z-stack maximum intensity projection image of a basket cell loaded with Alexa Fluor 594. (b) Confocal Z-stack maximum intensity projection image of the two-photon-imaged cell after fixation and visualization of the biocytin. (c) The imaged boutons from a are shown at a higher magnification with the corresponding [Ca2+] transients. The presented Ca2+ traces are the averages of two individual traces for each bouton. Note the variability in the peak transients within a bouton string. (d) Post hoc immunohistochemical visualization of CB1 (green) in the imaged and biocytin-filled (red) boutons. (e) Variability in action potential-evoked [Ca2+] transients in axon terminals of basket (imaged in stratum pyramidale) and DLI (imaged in strata radiatum or lucidum) cells. Every trace represents a single cell (averages of 18–30 individual traces). (f) [Ca2+] transients of DLI cells are significantly larger compared with basket cells. (g) Mean [Ca2+] transients measured in axon terminals in strata pyramidale and radiatum in a basket and a DLI cell. (h) Peak [Ca2+] transients in basket cell boutons are smaller in stratum pyramidale compared with the dendritic layers. Open symbols indicate independent measurements (individual cells measured in either layer), while filled symbols represent cells, in which boutons in both strata were measured (basket: n=8; DLI: n=4). * indicates significant difference (paired t-test, P<0.01, n=8) between strata pyramidale and dendritic layers for basket cells. (i) The amplitude of [Ca2+] transients is independent of the CB1 immunoreactivity of the cells when all cells are analysed together. When basket and DLI cells are analysed separately, significant positive correlation (Spearman correlation ρ=0.55, P=0.006) was found in baskets, but not in DLI cells. (j) No significant correlation was found between G/Gmax and CB1 content at the level of individual boutons in all analysed basket cells. Each cell is colour coded and open symbols represent individual boutons. Error bars in f and h represent s.d. A594, Alexa Fluor 594; str. pyr., stratum pyramidale. Other str.: strata oriens, lucidum and radiatum. Scale bars, 20 μm (a,b); 5 μm (c,d).
Figure 5 Action potential-evoked [Ca 2+ ] transients are smaller in axon terminals of basket compared with DLI cells. (a) Two-photon Z-stack maximum intensity projection image of a basket cell loaded with Alexa Fluor 594. (b) Confocal Z-stack maximum intensity projection image of the two-photon-imaged cell after fixation and visualization of the biocytin. (c) The imaged boutons from a are shown at a higher magnification with the corresponding [Ca2+] transients. The presented Ca2+ traces are the averages of two individual traces for each bouton. Note the variability in the peak transients within a bouton string. (d) Post hoc immunohistochemical visualization of CB1 (green) in the imaged and biocytin-filled (red) boutons. (e) Variability in action potential-evoked [Ca2+] transients in axon terminals of basket (imaged in stratum pyramidale) and DLI (imaged in strata radiatum or lucidum) cells. Every trace represents a single cell (averages of 18–30 individual traces). (f) [Ca2+] transients of DLI cells are significantly larger compared with basket cells. (g) Mean [Ca2+] transients measured in axon terminals in strata pyramidale and radiatum in a basket and a DLI cell. (h) Peak [Ca2+] transients in basket cell boutons are smaller in stratum pyramidale compared with the dendritic layers. Open symbols indicate independent measurements (individual cells measured in either layer), while filled symbols represent cells, in which boutons in both strata were measured (basket: n=8; DLI: n=4). * indicates significant difference (paired t-test, P<0.01, n=8) between strata pyramidale and dendritic layers for basket cells. (i) The amplitude of [Ca2+] transients is independent of the CB1 immunoreactivity of the cells when all cells are analysed together. When basket and DLI cells are analysed separately, significant positive correlation (Spearman correlation ρ=0.55, P=0.006) was found in baskets, but not in DLI cells. (j) No significant correlation was found between G/Gmax and CB1 content at the level of individual boutons in all analysed basket cells. Each cell is colour coded and open symbols represent individual boutons. Error bars in f and h represent s.d. A594, Alexa Fluor 594; str. pyr., stratum pyramidale. Other str.: strata oriens, lucidum and radiatum. Scale bars, 20 μm (a,b); 5 μm (c,d).CC BY · PubMed Central
Figure 6 The CB 1 antagonist AM251 significantly increases [Ca 2+ ] transients in axon terminals of basket, but not those of DLI cells in the CA3 area. (a,b) The amplitude of [Ca2+] transients is larger in basket (a), but not in DLI cells (b) when [Ca2+] measurements were performed in 1 μM AM251 pre-incubated slices. (c–j) Effect of 100 nM AM251 on individual boutons in basket (c-f) and DLI cells (g–j) in stratum pyramidale (c,d,g,h) and in dendritic layers (e,f,i,j). The imaged boutons are labelled on the confocal Z-stack maximum intensity projection image (red, biocytin; green, CB1), and corresponding [Ca2+] transients are shown before (left traces) and after (right traces) AM251 application (c,e,g,i). Amplitude values of [Ca2+] transients recorded from individual boutons in control condition and after AM251 application are shown in d,f,h and j. AM251 significantly increases [Ca2+] transients in strata pyramidale (d, paired t-test, P=0.005, n=7 boutons) and lucidum (f, paired t-test, P=0.012, n=7 boutons) in basket cells. (k) AM251 effect on the amplitude of [Ca2+] transients at individual cells in strata pyramidale and lucidum/radiatum. Every symbol represents an individual cell. (l–m) The AM251 effect does not depend on either the peak [Ca2+] (l) or the relative CB1 content of the boutons (m). Measurements were performed in stratum pyramidale (circles) and radiatum/lucidum (triangles) for basket (black) and DLI (red) cells, respectively. When the correlation was analysed only for basket cells, no significant effect was seen. (n–o) Correlation analysis at the level of individual boutons revealed significant correlation between AM251 effect and G/Gmax in five out of nine cells (n). Each cell is colour coded and open symbols represent individual boutons. There was no correlation between AM251 effect and CB1 immunoreactivity in all analysed (n=7) cells (o). Error bars in a,b,d,f,h,j and k represent s.d. Scale bars, 5 μm (c,e,g,i). *denotes P<0.05.
Figure 6 The CB 1 antagonist AM251 significantly increases [Ca 2+ ] transients in axon terminals of basket, but not those of DLI cells in the CA3 area. (a,b) The amplitude of [Ca2+] transients is larger in basket (a), but not in DLI cells (b) when [Ca2+] measurements were performed in 1 μM AM251 pre-incubated slices. (c–j) Effect of 100 nM AM251 on individual boutons in basket (c-f) and DLI cells (g–j) in stratum pyramidale (c,d,g,h) and in dendritic layers (e,f,i,j). The imaged boutons are labelled on the confocal Z-stack maximum intensity projection image (red, biocytin; green, CB1), and corresponding [Ca2+] transients are shown before (left traces) and after (right traces) AM251 application (c,e,g,i). Amplitude values of [Ca2+] transients recorded from individual boutons in control condition and after AM251 application are shown in d,f,h and j. AM251 significantly increases [Ca2+] transients in strata pyramidale (d, paired t-test, P=0.005, n=7 boutons) and lucidum (f, paired t-test, P=0.012, n=7 boutons) in basket cells. (k) AM251 effect on the amplitude of [Ca2+] transients at individual cells in strata pyramidale and lucidum/radiatum. Every symbol represents an individual cell. (l–m) The AM251 effect does not depend on either the peak [Ca2+] (l) or the relative CB1 content of the boutons (m). Measurements were performed in stratum pyramidale (circles) and radiatum/lucidum (triangles) for basket (black) and DLI (red) cells, respectively. When the correlation was analysed only for basket cells, no significant effect was seen. (n–o) Correlation analysis at the level of individual boutons revealed significant correlation between AM251 effect and G/Gmax in five out of nine cells (n). Each cell is colour coded and open symbols represent individual boutons. There was no correlation between AM251 effect and CB1 immunoreactivity in all analysed (n=7) cells (o). Error bars in a,b,d,f,h,j and k represent s.d. Scale bars, 5 μm (c,e,g,i). *denotes P<0.05.CC BY · PubMed Central
Figure 7 Activation of the CB 1 significantly decreases [Ca 2+ ] transients in axon terminals of basket and DLI cells in the CA3 area. (a,b,d,e) Effect of the CB1 agonist WIN 55212-2 (10 and 100 nM) on [Ca2+] transients in individual basket (in stratum pyramidale) and DLI cells (in dendritic layers). The effect of 10 nM did not reach significance, but that of 100 nM was significant. (c,f) The WIN 55212-2 effect does not depend on the CB1 content of cells when analysis were either performed in all recorded cell (blue regression lines in c and f) or only for basket cells (black regression line in c). (g,h) The effect of 100 nM WIN 55212-2 can be reversed by the CB1 antagonist AM251 (1 μM). (i) The effect of 5 μM carbachol did not depend on the CB1 immunoreactivity of the cells. Error bars in b,e and h represent s.d. All scales for a,d and g are shown in d. *denotes P<0.05.
Figure 7 Activation of the CB 1 significantly decreases [Ca 2+ ] transients in axon terminals of basket and DLI cells in the CA3 area. (a,b,d,e) Effect of the CB1 agonist WIN 55212-2 (10 and 100 nM) on [Ca2+] transients in individual basket (in stratum pyramidale) and DLI cells (in dendritic layers). The effect of 10 nM did not reach significance, but that of 100 nM was significant. (c,f) The WIN 55212-2 effect does not depend on the CB1 content of cells when analysis were either performed in all recorded cell (blue regression lines in c and f) or only for basket cells (black regression line in c). (g,h) The effect of 100 nM WIN 55212-2 can be reversed by the CB1 antagonist AM251 (1 μM). (i) The effect of 5 μM carbachol did not depend on the CB1 immunoreactivity of the cells. Error bars in b,e and h represent s.d. All scales for a,d and g are shown in d. *denotes P<0.05.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 51 references

Cited by

See all 45

Metadata

Authors
Lenkey, N., Kirizs, T., Holderith, N., Máté, Z., Szabó, G., Vizi, E. S., Hájos, N., & Nusser, Z.
Affiliations
  • HUN-REN Institute of Experimental Medicine (HU)
  • Semmelweis University (HU)
Venue
Nature Communications
Published
2015-04-20
Volume
6
Issue
1
Pages
6557-6557
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2041300659
Cited by
45
References
51
Citations by year
2026: 1 · 2025: 2 · 2024: 2 · 2023: 1 · 2022: 3 · 2021: 6 · 2020: 2 · 2019: 8 · 2018: 3 · 2017: 9 · 2016: 5 · 2015: 3
FWCI
4.80
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Repository of the Academy's Library (Library of the Hungarian Academy of Sciences) (acceptedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion)
  • University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion, other-oa)
Funders
  • Wellcome Trust (094513, WT094513)
  • Magyar Tudományos Akadémia (LP2012-29, LP2012‐23)
  • Nemzeti Kutatási és Technológiai Hivatal (OMFB-01678/2009)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
Keywords
endocannabinoids, CB1 receptor, GABA release, cholecystokinin interneurons, basket cells, axon terminals, calcium imaging, AM251, CB1 agonists, receptor colocalization, tonic inhibition
MeSH terms
Red Fluorescent Protein, Animals, Animals, Newborn, Calcium, Female, gamma-Aminobutyric Acid, Hippocampus, Luminescent Proteins, Male, Mice, Transgenic, Neurons, Presynaptic Terminals, Receptor, Cannabinoid, CB1, Mice, Endocannabinoids

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.